Clinical Trial Update: VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing VIC regimen to bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• VIC regimen

Snippet

Sponsor: Fudan University | Conditions: Colorectal Cancer | Phase 3 | Status: UNKNOWN